These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 31994421)
1. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Jackson K; Bahna SL Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421 [No Abstract] [Full Text] [Related]
2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database. Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960 [TBL] [Abstract][Full Text] [Related]
4. Biologics in allergic rhinitis. Bayar Muluk N; Cingi C Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947 [TBL] [Abstract][Full Text] [Related]
5. Strategies for choosing a biologic for your patient with allergy or asthma. Saco T; Ugalde IC; Cardet JC; Casale TB Ann Allergy Asthma Immunol; 2021 Dec; 127(6):627-637. PubMed ID: 34642091 [TBL] [Abstract][Full Text] [Related]
6. A drug safety review of treating eosinophilic asthma with monoclonal antibodies. Mitchell P; Leigh R Expert Opin Drug Saf; 2019 Dec; 18(12):1161-1170. PubMed ID: 31594389 [No Abstract] [Full Text] [Related]
8. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma. Domingo C Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572 [TBL] [Abstract][Full Text] [Related]
9. Biologics for Asthma and Allergic Skin Diseases in Children. De Keyser HH; Chipps B; Dinakar C; Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34663682 [TBL] [Abstract][Full Text] [Related]
10. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database. Park S; Kim Y; Lee GH; Choi SA Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636 [TBL] [Abstract][Full Text] [Related]
12. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951 [TBL] [Abstract][Full Text] [Related]
13. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations. Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642 [TBL] [Abstract][Full Text] [Related]
15. Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit? Bergmann KC; Maurer M; Church MK; Zuberbier T J Investig Allergol Clin Immunol; 2020 Aug; 30(4):285-287. PubMed ID: 32723701 [No Abstract] [Full Text] [Related]
16. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria. Chiarella SE Allergy Asthma Proc; 2019 Nov; 40(6):485-489. PubMed ID: 31690400 [TBL] [Abstract][Full Text] [Related]
17. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment. Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506 [TBL] [Abstract][Full Text] [Related]
18. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis. Rivero A; Liang J Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644 [TBL] [Abstract][Full Text] [Related]
19. Biologics for the Treatments of Allergic Conditions: Severe Asthma. Caminati M; Bagnasco D; Rosenwasser LJ; Vianello A; Senna G Immunol Allergy Clin North Am; 2020 Nov; 40(4):549-564. PubMed ID: 33012319 [TBL] [Abstract][Full Text] [Related]
20. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]